AGENUS INC Files 8-K for Material Definitive Agreement

Ticker: AGEN · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1098972

Sentiment: neutral

Topics: material-definitive-agreement, filing, corporate-news

TL;DR

AGENUS INC. just signed a big deal, filing an 8-K to let everyone know.

AI Summary

On June 3, 2025, AGENUS INC. (formerly ANTIGENICS INC /DE/) entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices at 3 Forbes Road, Lexington, MA, filed an 8-K report detailing this agreement. The filing also includes Regulation FD disclosures and financial statements.

Why It Matters

This filing indicates a significant new contract or partnership for AGENUS INC., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial 8-K filing.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by AGENUS INC.?

The filing states that AGENUS INC. entered into a material definitive agreement on June 03, 2025, but the specific details of this agreement are not provided in the provided text.

When was AGENUS INC. formerly known as ANTIGENICS INC /DE/?

The date of the name change from ANTIGENICS INC /DE/ to AGENUS INC was November 15, 1999.

What is AGENUS INC.'s primary business classification?

AGENUS INC. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.

Where are AGENUS INC.'s principal executive offices located?

AGENUS INC.'s principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts, 02421.

What is the SEC file number for AGENUS INC.?

The SEC file number for AGENUS INC. is 000-29089.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding AGENUS INC (AGEN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing